TIL - Instil Bio, Inc.
IEX Last Trade
21.525
-44.595 -207.178%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:20:50 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$66.12
-44.60
-67.45%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
6.21%
1 Month
-16.35%
3 Months
-68.32%
6 Months
122.91%
1 Year
208.31%
2 Year
118.94%
Key data
Stock price
$21.52
DAY RANGE
$21.18 - $66.12
52 WEEK RANGE
$7.74 - $92.00
52 WEEK CHANGE
$193.46
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
Company detail
CEO: Bronson Crouch
Region: US
Website: instilbio.com
Employees: 410
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: instilbio.com
Employees: 410
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL) Product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, and cervical cancer.
Recent news